University of Pavia

Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP28

Retrieved on: 
수요일, 11월 29, 2023
Environment, Climate Change, Infectious Diseases, Hospitals, Environmental Issues, Natural Disasters, Sustainability, General Health, Pharmaceutical, Health, Pfizer, Climate change, WHO, Patient, Climate, GSK, Novartis, BSI, Knowledge, News, NHS England, Task, Samsung Biologics, Multimedia, Air pollution, Life-cycle assessment, University of Pavia, LCA, Novo Nordisk, Johnson & Johnson, AstraZeneca, Global warming potential, Infection, University, Partnership, Water, UNICEF, Working Group, Merck Group, World Health Organization, COP26, Carbon, Reckitt, COP28, Private sector, Task force, PEG, Roche, GHG, Pharmaceutical industry, Renewable energy, Sanofi, Takeda, Lonza

This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries.

Key Points: 
  • This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries.
  • Today’s commitments ahead of COP28, which marks the first global climate conference to have an official focus on health, build on bold action already taken by the group to decarbonise healthcare .
  • The Working Group aims to accelerate the delivery of sustainable healthcare in China, with broader global impact.
  • Ahead of COP28, new Task Force members Bupa, Novartis and Reckitt joined the collaboration.

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

Retrieved on: 
화요일, 9월 12, 2023
Non-executive director, University, AIM, Honours degree, Health, Forster, MBA, Research, Sale, Triple accreditation, Development, Henley Business School, Committee, University of Pavia, Therapy, NYSE, UK, H5 (US company), Management, OSCHR, Protalix BioTherapeutics

Zeev Bronfeld, the current Chairman of the Company's Board of Directors, will retire on the same day.

Key Points: 
  • Zeev Bronfeld, the current Chairman of the Company's Board of Directors, will retire on the same day.
  • "We are very pleased that Eliot will be joining our Board of Directors," commented Dror Bashan, Protalix's President and Chief Executive Officer.
  • He will be a valuable contribution to our Board of Directors as we leverage our development successes to strengthen our research and development efforts."
  • "I am delighted and honored to join Protalix as Chairman of its Board of Directors, and very much look forward to working with Protalix's talented officers, directors and employees," said Dr. Forster.

Robert S. Ruffini Innovation and Entrepreneurship Award

Retrieved on: 
화요일, 7월 11, 2023
Other Manufacturing, Technology, Semiconductor, Engineering, Satellite, Chemicals, Plastics, Aerospace, Nanotechnology, Manufacturing, Electronic Design Automation, University of Pavia, University, FASM, ENTREPRENEURSHIP, Research, University of Padua, Entrepreneurship, LEP, Industrial, Laboratory, Conference, Heat

The event was attended by delegates from around the world, who shared presentations on the latest advances in the field.

Key Points: 
  • The event was attended by delegates from around the world, who shared presentations on the latest advances in the field.
  • With a focus on innovation and collaboration, the conference was a great success, showcasing the latest research and developments in this area of induction heating technology.
  • This year, HES-23 and Fluxtrol Inc. have partnered to provide a competition-based award and recognition program, aptly named the ROBERT S. RUFFINI INNOVATION AND ENTREPRENEURSHIP AWARD, for aspiring young innovators and professionals.
  • The esteemed award was presented to the winner Mikus Milgrāvis for his project and demonstration of a crucible stirrer.

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

Retrieved on: 
금요일, 6월 30, 2023
Research, Neurology, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Real, Abstract, EAN, Migraine, EHF, University of Pavia, University, Teva, Disability, PEARL, Quality of life, CGRP, Month, Behavioural sciences, Female, Congress, European Academies' Science Advisory Council, Patient, Mab, FINESSE, Calcitonin gene-related peptide, Safety, MMD, Pharmaceutical industry, Health insurance, Aroma compound, Cultured pearl, Brain

Not only was fremanezumab effective in preventing migraine attacks in patients with chronic and episodic migraine, but it has also shown to be effective in reducing the severity and duration of remaining migraine attacks.

Key Points: 
  • Not only was fremanezumab effective in preventing migraine attacks in patients with chronic and episodic migraine, but it has also shown to be effective in reducing the severity and duration of remaining migraine attacks.
  • Four abstracts from the third interim analysis of the PEARL study will be presented at the 9th European Academy of Neurology (EAN) Congress in Budapest, Hungary.
  • 968 patients (87.3% female) out of the 1140 study patients had available data to include in the 3rd interim analysis.
  • The mean monthly duration of remaining migraine attacks and monthly mean score for peak headache severity of remaining migraine attacks decreased at 12 months after fremanezumab initiation.

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

Retrieved on: 
목요일, 6월 8, 2023
Drug development, University, Gene, CMC, Survival, Quality of life, AAV, Pharmacist, Lentivirus, Novartis, MD, Patient, Cell, University of Pavia, Therapy, CADL, Prostate cancer, Orchard, Candel, Doctor of Philosophy, Fellow of the Academy of Medical Sciences

“We are pleased to welcome Nicoletta as a new member of Candel’s Board,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel.

Key Points: 
  • “We are pleased to welcome Nicoletta as a new member of Candel’s Board,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel.
  • “Her wealth of strategic and hands-on industry experience in drug development and manufacturing makes her an important addition to our Board as we advance our late-stage oncology programs.
  • She oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical research and development.
  • She is also a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

Retrieved on: 
수요일, 5월 17, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, University, Office for Strategic Coordination of Health Research, Doctor of Philosophy, Bio, Liver disease, CSO, Henley Business School, Hope, Physiology, MBA, Multimedia, Chairperson, Neurophysiology, MD, Patient, University of Pavia, Liver, Therapy, News, Pharmaceutical industry, Ochre, OSCHR

Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors.

Key Points: 
  • Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230516005212/en/
    Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors (Photo: Business Wire)
    The news follows the recent appointment of Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors, and David Coughlan, PhD as VP of Translational Development, as Ochre Bio continues to strengthen its leadership.
  • We are humbled to have him as part of the Ochre team.”
    Eliot Forster said, "I am honoured to join Ochre Bio as Chairperson.
  • He is also a Board member of OSCHR (Office for Strategic Coordination of Health Research), and the National Genomics Board.

Univibes: US Students Flock to Asian and European Universities to Improve Career Prospects

Retrieved on: 
금요일, 9월 16, 2022
NHL Stenden University of Applied Sciences, University, NHL, Applied science, EU Business School, Soongsil University, Ajou University, Student, University of Pavia, Insurance, Housing

In a foreign country, these obstacles are all the more difficult to overcome.

Key Points: 
  • In a foreign country, these obstacles are all the more difficult to overcome.
  • Unfortunately, students rarely receive comprehensive assistance for these challengesthis is where Univibes' tailored services come in.
  • The Univibes team is focused on helping every candidate receive scholarships and grants on their journey into academia.
  • Univibes partners with universities, insurance companies and real estate agencies to offer comprehensive support service.

HUDI: The Universal Basic Income Experiment in Crypto Shows First Results

Retrieved on: 
금요일, 5월 27, 2022
Crypto, Digital, UBI, Cryptocurrency, GDPR, Privacy, Data, Philosophy, Amazon, Instagram, Compliance, University, Organization, University of Pavia, Google, Sale, LinkedIn, CEO, Netflix

HUDI, the first data-driven universal basic income crypto project, shares compelling data monetizations insights in a new report: 240.000 users and 50.000 data requests

Key Points: 
  • HUDI allows people to regain control over their data and monetize it in crypto ($HUDI).
  • The idea of a universal basic income (UBI) is not new, but this is the first UBI empowered by the data economy.
  • "These results have been achieved with a handful of data," claims Franky Ballarani, co-founder and CEO of HUDI.
  • HUDI will disintermediate and democratize the data market, to the point where every person can cover basic living expenses, thanks to Human Data Income."

Fullpower®-AI Announces New VP of Business Development, Dr. Silvia Veronese

Retrieved on: 
월요일, 1월 24, 2022
Woman, Business development, Platform as a service, Research, Technology, IOT, IP, Communication Service for the Deaf, IBM, MBA, University of Pavia, CEO, University, Solution, Information management, Digital security, VP, CIO magazine, View, Fullpower Technologies, Mathematics, Artificial intelligence, Silicon, Environment, University of Management and Technology (Lahore), Multimedia, HP, Patent, Computer, B2B, Senior, Medical device, Management, AI, Platform, Thales of Miletus

SANTA CRUZ, Calif., Jan. 24, 2022 /PRNewswire/ --Fullpower-AI announced Silvia Veronese is joining Fullpower-AI as VP of Business Development.

Key Points: 
  • SANTA CRUZ, Calif., Jan. 24, 2022 /PRNewswire/ --Fullpower-AI announced Silvia Veronese is joining Fullpower-AI as VP of Business Development.
  • Before that, Dr. Veronese held executive positions at HP, where she created the function of customer success responsible for the $1B product line in digital security and information management.
  • In addition, Dr. Veronese was a research professor of mathematics at the University of Utah.
  • "Welcome, Dr. Veronese; your expertise adds exceptional talent to Fullpower-AI's stellar team," said Philippe Kahn, founder, and CEO of Fullpower-AI.